Literature DB >> 9556609

Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor.

G Fuh1, B Li, C Crowley, B Cunningham, J A Wells.   

Abstract

Vascular endothelial growth factor (VEGF) is a dimeric hormone that controls much of vascular development through binding and activation of its kinase domain receptor (KDR). We produced analogs of VEGF that show it has two receptor-binding sites which are located near the poles of the dimer and straddle the interface between subunits. Deletion experiments in KDR indicate that of the seven IgG-like domains in the extracellular domain, only domains 2-3 are needed for tight binding of VEGF. Monomeric forms of the extracellular domain of KDR bind approximately 100 times weaker than dimeric forms showing a strong avidity component for binding of VEGF to predimerized forms of the receptor. Based upon these structure-function studies and a mechanism in which receptor dimerization is critical for signaling, we constructed a receptor antagonist in the form of a heterodimer of VEGF that contained one functional and one non-functional site. These studies establish a functional foundation for the design of VEGF analogs, mimics, and antagonists.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9556609     DOI: 10.1074/jbc.273.18.11197

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling.

Authors:  Holly S Haase; Kimberly J Peterson-Kaufman; Sheeny K Lan Levengood; James W Checco; William L Murphy; Samuel H Gellman
Journal:  J Am Chem Soc       Date:  2012-05-01       Impact factor: 15.419

2.  Differential effects of a soluble or immobilized VEGFR-binding peptide.

Authors:  Justin T Koepsel; Eric H Nguyen; William L Murphy
Journal:  Integr Biol (Camb)       Date:  2012-06-25       Impact factor: 2.192

Review 3.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

4.  Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects.

Authors:  De-Chao Yu; Jung-Sun Lee; Ji Young Yoo; Hyewon Shin; Hongxin Deng; Yuquan Wei; Chae-Ok Yun
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

5.  Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases.

Authors:  Heli Liu; Xiaoyan Chen; Pamela J Focia; Xiaolin He
Journal:  EMBO J       Date:  2007-01-25       Impact factor: 11.598

6.  Human retinal epithelium produces and responds to placenta growth factor.

Authors:  Margrit Hollborn; Solveig Tenckhoff; Marlen Seifert; Stephanie Köhler; Peter Wiedemann; Andreas Bringmann; Leon Kohen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-12-09       Impact factor: 3.117

7.  Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.

Authors:  Niv Papo; Adam P Silverman; Jennifer L Lahti; Jennifer R Cochran
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

Review 8.  Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites.

Authors:  Caroline A C Hyde; Alexandra Giese; Edward Stuttfeld; Johan Abram Saliba; Denis Villemagne; Thomas Schleier; H Kaspar Binz; Kurt Ballmer-Hofer
Journal:  Mol Cell Biol       Date:  2012-07-16       Impact factor: 4.272

9.  Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Authors:  Romulo J C Albuquerque; Takahiko Hayashi; Won Gil Cho; Mark E Kleinman; Sami Dridi; Atsunobu Takeda; Judit Z Baffi; Kiyoshi Yamada; Hiroki Kaneko; Martha G Green; Joe Chappell; Jörg Wilting; Herbert A Weich; Satoru Yamagami; Shiro Amano; Nobuhisa Mizuki; Jonathan S Alexander; Martha L Peterson; Rolf A Brekken; Masanori Hirashima; Seema Capoor; Tomohiko Usui; Balamurali K Ambati; Jayakrishna Ambati
Journal:  Nat Med       Date:  2009-08-09       Impact factor: 53.440

10.  Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.

Authors:  Lokesh Jain; Tristan M Sissung; Romano Danesi; Elise C Kohn; William L Dahut; Shivaani Kummar; David Venzon; David Liewehr; Bevin C English; Caitlin E Baum; Robert Yarchoan; Giuseppe Giaccone; Jürgen Venitz; Douglas K Price; William D Figg
Journal:  J Exp Clin Cancer Res       Date:  2010-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.